SNW.DE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 11:35):

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally...

Stats
Today's Volume	4 744.00
Average Volume	3 413.00
Market Cap	106.90B
EPS	€2.55 ( 2023-10-27 )
Last Dividend	€3.56 ( 2023-05-30 )
Next Dividend	€0 ( N/A )
P/E	19.87
ATR14	€0.203 (0.24%)

Sanofi SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Sanofi SA Financials

Annual	2023
Revenue:	€43.07B
Gross Profit:	€28.83B (66.95 %)
EPS:	€4.31

Q4	2023
Revenue:	€22.88B
Gross Profit:	€14.68B (64.16 %)
EPS:	€1.570

Q3	2023
Revenue:	€12.70B
Gross Profit:	€8.86B (69.75 %)
EPS:	€2.01

Q2	2023
Revenue:	€10.68B
Gross Profit:	€7.41B (69.41 %)
EPS:	€2.74

Financial Reports:

No articles found.

Sanofi SA Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€3.56 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Sanofi SA Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.30 - Increase likely (46.04%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€2.07	2008-05-16
Last Dividend	€3.56	2023-05-30
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	€45.47	--
Avg. Dividend % Per Year	0.00%	--
Score	3.45	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.30
Div. Directional Score	9.29	--

Next Divdend (Est)
(2025-03-31)

€3.71 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.45

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
NMM.DE	Ex Dividend Knight	2023-09-06	Quarterly	0.00%
AOMD.DE	No Dividend Player	2023-07-17	Sporadic	0.00%
XONA.DE	Ex Dividend Knight	2023-08-15	Quarterly	0.00%
GUI.DE	Ex Dividend Knight	2023-08-24	Semi-Annually	0.00%
PPX.DE	Ex Dividend Knight	2023-05-02	Semi-Annually	0.00%
BSN.DE	Ex Dividend Junior	2023-05-09	Annually	0.00%
IC1B.F	Ex Dividend Junior	2023-08-31	Annually	0.00%
SLL.DE	Ex Dividend Knight	2023-05-23	Sporadic	0.00%
DB1.DE	Ex Dividend Junior	2023-05-17	Annually	0.00%
LHOG.F	Ex Dividend Junior	2023-08-24	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.139	1.500	7.23	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0627	1.200	7.91	9.49	[0 - 0.3]
returnOnEquityTTM	0.108	1.500	9.92	10.00	[0.1 - 1]
payoutRatioTTM	0.579	-1.000	4.21	-4.21	[0 - 1]
currentRatioTTM	1.277	0.800	8.62	6.89	[1 - 3]
quickRatioTTM	0.390	0.800	-2.41	-1.928	[0.8 - 2.5]
cashRatioTTM	0.363	1.500	9.10	10.00	[0.2 - 2]
debtRatioTTM	0.132	-1.500	7.80	-10.00	[0 - 0.6]
interestCoverageTTM	7.43	1.000	8.36	8.36	[3 - 30]
operatingCashFlowPerShareTTM	8.20	2.00	7.27	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.60	2.00	7.20	10.00	[0 - 20]
debtEquityRatioTTM	0.225	-1.500	9.10	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.678	1.000	2.03	2.03	[0.2 - 0.8]
operatingProfitMarginTTM	0.231	1.000	7.39	7.39	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.615	1.000	7.69	7.69	[0.2 - 2]
assetTurnoverTTM	0.452	0.800	-0.318	-0.255	[0.5 - 2]
Total Score				11.29

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	13.87	1.000	8.70	0	[1 - 100]
returnOnEquityTTM	0.108	2.50	9.95	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.60	2.00	8.13	10.00	[0 - 30]
dividendYielPercentageTTM	4.05	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	8.20	2.00	7.27	10.00	[0 - 30]
payoutRatioTTM	0.579	1.500	4.21	-4.21	[0 - 1]
pegRatioTTM	0.633	1.500	9.11	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.180	1.000	8.01	0	[0.1 - 0.5]
Total Score				7.30

Sanofi SA

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.